The clinical performance is complex and often involves multiple systemic burdens. Early identification and normalisation of the diagnosis are essential for improving the prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging inspections, laboratory tests and pathological activation.
The platform can assist in matching authoritative experts and teams at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune diseases that have previously been difficult to treat have been significantly improved. Treatment requires close monitoring of therapeutic efficacy and adverse reactions, adapting to timely regimens according to changes in conditions.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of gestational cancers. The platform serves the China International Medical Service System, a team of nationally authoritative experts in the field of autoimmune and rheumatic immunity, to provide patients with the following services: Remote pre-diagnosis: 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.